BLAINJECTIONINJECTABLE
Approved
Sep 2017
Lifecycle
Peak
Competitive Pressure
30/100
Clinical Trials
2
Data completeness
6/8 — Strong
MVASI (bevacizumab-awwb) by Amgen is vascular endothelial growth factor-directed antibody interactions [moa]. Approved for vascular endothelial growth factor inhibitor [epc]. First approved in 2017.
Drug data last refreshed 6h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
MVASI (bevacizumab-awwb) is a monoclonal antibody biosimilar approved in 2017 that inhibits vascular endothelial growth factor (VEGF) to block tumor angiogenesis. It is used across multiple cancer indications where VEGF-driven neovascularization drives disease progression. The drug works by binding VEGF and preventing its interaction with endothelial growth factor receptors.
$13MPart D
PeakStable
MVASI is at peak lifecycle with modest Part D volume (2,039 claims in 2023), suggesting a mature market with stable but not expanding commercial opportunity.
Mechanism of Action
Vascular Endothelial Growth Factor-directed Antibody Interactions
Pharmacologic Class:
Vascular Endothelial Growth Factor Inhibitor
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (2)
Study of Sotorasib, Panitumumab and FOLFIRI Versus FOLFIRI With or Without Bevacizumab-awwb in Treatment-naïve Participants With Metastatic Colorectal Cancer With KRAS p.G12C Mutation
Started Jul 2024
450 enrolled
Metastatic Colorectal Cancer
A Phase I/II Study of AMG 510 in Combination With MVASI in Patients With Advanced, Unresectable or Metastatic KRAS G12C Mutant NSCLC With Asymptomatic Brain Metastasis
Started Jun 2022
0Non Small Cell Lung Cancer
Why This Matters for Your Career
Worked on MVASI at Amgen? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.